Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.

Fiche publication

Date publication

octobre 2025

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
Ambrosini M, Blons H, Garinet S, Mulot C, Le Corre D, Mouillet-Richard S, Pietrantonio F, Sroussi M, Lepage C, Laurent-Puig P, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41167084

Résumé

The paradigm of molecular negative hyperselection, beyond RAS and BRAF, identifies metastatic colorectal cancer (mCRC) patients with the greatest benefit from anti-epidermal growth factor receptor (anti-EGFR) agents. We hypothesize that applying this model to stage III colon cancer (CC) might identify a subgroup deriving benefit from anti-EGFRs in the adjuvant setting.